Genomic Health (NASDAQ: GHDX) and Advaxis (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Volatility and Risk

Genomic Health has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Advaxis has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Profitability

This table compares Genomic Health and Advaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genomic Health -1.30% -1.79% -1.41%
Advaxis -655.66% -93.54% -64.49%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Genomic Health and Advaxis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genomic Health 1 5 1 0 2.00
Advaxis 0 0 2 0 3.00

Genomic Health presently has a consensus price target of $32.67, suggesting a potential upside of 8.85%. Advaxis has a consensus price target of $21.00, suggesting a potential upside of 602.34%. Given Advaxis’ stronger consensus rating and higher probable upside, analysts plainly believe Advaxis is more favorable than Genomic Health.

Earnings and Valuation

This table compares Genomic Health and Advaxis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genomic Health $327.87 million 3.18 -$13.91 million ($0.12) -250.08
Advaxis $3.99 million 30.78 -$73.55 million ($2.29) -1.31

Genomic Health has higher revenue and earnings than Advaxis. Genomic Health is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

89.8% of Genomic Health shares are held by institutional investors. Comparatively, 41.9% of Advaxis shares are held by institutional investors. 46.2% of Genomic Health shares are held by company insiders. Comparatively, 7.2% of Advaxis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Genomic Health beats Advaxis on 8 of the 13 factors compared between the two stocks.

About Genomic Health

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

About Advaxis

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.